Wednesday, 14 April 2021

BioLargo Inc. to Present at Benzinga Cleantech Small Cap Conference on April 22nd at 11:20am EST

Westminster, CA – April 14, 2021– BioLargo, Inc. (OTCQB:BLGO), developer of sustainable clean technologies and a full-service environmental engineering company will be presenting at the Benzinga Cleantech Small Cap Conference on Earth Day, April 22, 2021, at 11:20am EST. The company invites its shareholders and all interested parties to learn more about BioLargo, cleantech, and environmental remediation investment opportunities.

“If you haven’t heard about BioLargo in a while, then you only know half the story,” said BioLargo CEO Dennis P. Calvert. “We’ve grown into a serious contender in the cleantech solutions industry, and we have new water remediation technologies that can help solve a lot of pressing challenges in the world. We are excited to share our progress with the markets as we continue to provide knockout solutions to challenging global problems.”

Benzinga hosts investor conferences focused on clean technologies, also known as “cleantech”, which are technologies that foster positive environmental outcomes such as reduced energy usage, water resource stewardship, and minimization of waste. Industry leaders around the world are increasingly focused on cleantech as the demand for these technologies rises globally each year.

Sign up for free: https://www.benzinga.com/events/small-cap/clean-tech/

 

About the Benzinga Cleantech Small Cap Conference

The Benzinga Cleantech Small Cap Conference bridges the gap between cleantech companies, investors, and traders. Discover the companies in the cleantech industry who are moving the world forward through accessible green energy, energy efficiency, and innovative sustainability solutions.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Monday, 5 April 2021

BioLargo reports 2020 results that sees revenue rise 31% as its cleantech products gain traction

 

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive the group posted full-year 2020 financial results on Wednesday that saw its consolidated revenue rise 31% year-over-year as its cleantech technologies gained commercial traction. Calvert says in terms of debt, in March, BioLargo retired an additional $650,000 in debt. Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA/PPP loans and fixed-price convertible debt now remain on BioLargo's balance sheet.

Wednesday, 31 March 2021

BioLargo 2020 Annual Report Highlights Expanding Commercial Traction for its Cleantech Technologies, Record Revenue Growth and Improved Balance Sheet







Westminster, CA – March 31, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC today for the year ended December 31, 2020 (www.biolargo.com/sec-filings). The company has provided highlights from the Annual Report along with commentary on the recent advancements in its mission to “make life better” through its innovative cleantech products and services. The company also announced an investor webcast to be held on Wednesday March 31, 2021, at 2:00 pm Pacific / 5:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/40636.

BioLargo CEO Dennis Calvert commented, “In the last year, we developed and refined new technologies that are now ready for commercial trials, formalized strategic relationships to expand sales and revenues, arranged for demonstration pilot projects for our AOS water treatment system, increased revenues, including those of our flagship product, CupriDyne Clean. We also began the process to register our CupriDyne technology with the EPA to make advanced sanitization and disinfection claims. All the while, we and the world struggled through the challenges presented by the COVID-19 pandemic.”

He continued, “We believe our future revenue growth will be driven by the portfolio of leading cleantech technologies we’ve developed and increasing sales activities through our expanding network of strategic partners. One such example is the impending commercial of launch of our PFAS water treatment solution, the AEC, which is set to begin its first demonstration pilots and commercial trials soon. These are great times for BioLargo, as our products and technologies are well positioned to find adoption with customers and partners and become leading solutions in their category.”

Key financial highlights:

  • Consolidated revenue for the year ended December 31, 2020 was $2,432,000, which is a 31% increase over the same period in 2019. In the quarter ended December 31, 2020, BioLargo generated approximately $900,000 in company-wide revenue, a 36% increase compared to the prior quarter.
  • In 2020 the company retired over $3 million in debt, from $4.8 million down to $1.7 million. In March 2021, the company retired an additional $650,000 in debt. Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA/PPP loans and fixed-price convertible debt now remain on BioLargo’s balance sheet. Of the fixed price convertible debt, $100,000 will convert to equity automatically at the April 20, 2021 maturity date, the $406,000 due in August 2021 may be converted by the investors at a fixed price of $0.14 at any time, and $50,000 is due in two years.
  • In 2020, non-cash charges to earnings were $5.48 million which make up the 56% of the company’s total net loss. As the company continues to reduce its reliance on expensive debt instruments to finance operating costs, and as revenues increase, it expects its net loss and reliance on debt-based financing to decrease going forward.
  • BioLargo Engineering recorded total sales of $615,000 with third-party customers, and an additional $435,000 of intersegment revenue that is eliminated in consolidation. Intersegment revenues are primarily composed of billings to other BioLargo subsidiaries for work related to research and development expenses and commercialization of our AOS and AEC water treatment technologies.
  • ONM Environmental generated $1.5 million in revenue in 2020, and had a net loss of $483,000, as it continued expanding sales and operations capacity as the company grew sales of its air quality control products and services.
  • BioLargo owns a minority interest of approximately 45% in its subsidiary Clyra Medical, which develops and markets medical products based on BioLargo’s technologies through a license agreement calling for 6% royalty payments.  Clyra reported a net loss of $2.14 million for 2020, representing 22% of BioLargo’s total net loss for 2020, as its financial results are currently reported on a consolidated basis. BioLargo is not obligated to provide working capital to Clyra or pay its debts.

Key commercial, operational, and developmental highlights:

  • The BioLargo Aqueous Electrostatic Concentrator (AEC), our technology that removes toxic ‘forever chemicals’ (PFAS) that are commonly found in drinking water, ground water and industrial wastewater, is now in the final stages of development prior to commercial sales. The technology has been validated by third-party studies, and the first pilot units are being constructed for field testing and demonstration at participating pilot sites. The market for PFAS water treatment is expected to explode in the coming years because of tightening regulations on these. The company believes the AEC will represent the low cost, high impact option to help solve this crisis around the world.
  • The first commercial-scale Advanced Oxidation System (AOS) unit, BioLargo’s energy- and cost-efficient water treatment technology that removes hard-to-treat micropollutants, was deployed at a municipal wastewater treatment plant near Montréal, Québec as part of a demonstration pilot run by the renowned Centre des Technologies de l’Eau (CTE). The company is also on track for commencement of the AOS zero liquid discharge system project at poultry farm in Alberta, Canada, estimated to generate a half million dollars in revenue.
  • BioLargo established a partnership with Garratt-Callahan, a national industrial water treatment company, to develop and sell custom wastewater treatment equipment to recycle water from commercial facilities and is also working with them to expand sales of other BioLargo products.
  • ONM Environmental began servicing two very large municipal waste handling clients recently with its CupriDyne Clean odor and VOC control products and accompanying construction services.
  • Developed relationships with strategic partners, BKT South Korea, and Garratt-Callahan.
  • ONM Environmental expanded the portfolio of air quality control equipment and technologies it offers its customers to include modular, portable misting trailers as well as the trash truck and trash bin odor control system EcoMist®.
  • BioLargo Engineering continues to win major contracts with industrial clients, building a backlog of pending projects totaling more than $2 million over approximately the next 12-18 months. The group remains busy supporting BioLargo’s emerging commercial activities for the AEC and AOS water treatment systems.
  • BioLargo management is actively engaged with the EPA to expand its regulated claims for a series of products, including Clyraguard.

Mr. Calvert commented, “We continue to expand our intellectual property portfolio and are proud of our accomplishments. However, we also believe we have only scratched the surface of our revenue and profit potential and that our future is very bright. We’ve done the hard work, and now it’s time execute on the promise of our technologies and grow this company.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Tuesday, 30 March 2021

BioLargo Year End 2020 Earnings Results Webcast and Conference Call Wednesday, March 31, 2021 - 5:00 PM Eastern Time

Westminster, CA – March 30, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company to host investor webcast and conference call on Wednesday March 31, 2021, at 2:00 pm PST / 5:00 pm EST, open to the public. BioLargo will issue full-year 2020 results after the market closes on Tuesday, March 30, 2021. A webcast and conference call will be held to review the company’s financial results, discuss recent events, and conduct a question-and-answer session.

The webcast, accompanying presentation materials, and teleconference replay will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio video software.


To participate in the live webcast and teleconference:

Webcast Link:                                         https://www.webcaster4.com/Webcast/Page/2448/40636

Teleconference Domestic:                         844-369-8770

Teleconference International:                 862-298-0840


To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration:                         Thursday, March 31, 2022

Webcast Link:                                         https://www.webcaster4.com/Webcast/Page/2448/40636

Teleconference Replay Expiration:         Wednesday, April 14, 2021

Teleconference Replay Domestic:         877-481-4010

Teleconference Replay International:         919-882-2331

Replay Passcode:                                         40636


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 24 March 2021

Wes Larsen Joins BioLargo as Head of BioLargo Engineering’s West Coast Office

We are happy to announce the addition of a new key team member at BioLargo Engineering, Science & Technologies. Wes Larsen is joining us as BioLargo Engineering’s Vice President of West Coast Operations.

Given the scope of the commercial opportunities which are continuing to expand at BioLargo Engineering, especially in the State of California, the time was right to bring on an experienced project manager who could extend the company’s reach on the west coast. Wes brings significant additional talent and experience to the BioLargo family and will allow the company to address immediate environmental engineering opportunities in the region.

Wes has over 30+ years of experience in the management, engineering and construction of major refining, petrochemical, and power generation projects, both domestic and international. His experience extends to areas such as refinery modernization and revamp, air quality compliance, hydrogen reforming units, clean fuels, pipeline, oil field, chemical, LNG facilities, gas turbine combined cycle and cogeneration facilities, and coal power plants. 

BioLargo’s environmental subsidiaries – BioLargo Engineering, ONM Environmental, and BioLargo Water – continue to expand the scope of their capabilities. Bringing on experienced project management professionals like Wes is integral to our goal of growing our company’s ability to solve environmental challenges while creating value for our shareholders.

Wednesday, 17 March 2021

BioLargo to Present at Virtual Investor Summit on March 25, 2021 at 1:30 PM ET

CEO Dennis Calvert to Highlight the Company’s Sustainable Technologies and Commercialization Traction

Westminster, CA – March 17, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced that its CEO, Dennis Calvert, will present live to an online audience at the Q1 Virtual Investor Summit being held March 23-25, 2021 by the Investor Summit Group. The fully immersive conference features live presentations from CEOs of small- and mid-cap companies across multiple industries and one-on-one meetings with qualified investors. 

 

BioLargo Presentation at the Q1 Virtual Investor Summit 

·         DATE: Thursday, March 25, 2021 

·         TIME: 1:30 PM Eastern Time  

·         REGISTRATION: https://investorsummitgroup.com/register/  

 

Calvert will provide an overview of the company’s cutting-edge cleantech technologies and the successes the company has had in deploying them around the country to solve environmental challenges.

  

The Virtual Investor Summit is an exclusive, independent investor conference dedicated to connecting small-cap and microcap companies with qualified investors. The Q1 Virtual Investor Summit will feature approximately 100 companies and over 300 institutional, family office, high net worth investors and registered investment advisers. To register for the event, visit www.investorsummitgroup.com  

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday, 9 March 2021

BioLargo, Inc. Discusses Commercial PFAS Treatment Trials and Garratt-Callahan Partnership with The Stock Day Podcast

 

Phoenix, AZ -- March 09, 2021 -- The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB:BLGO), a company that invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, air quality control, and infection control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly.  

Jolly began the interview by asking about BioLargo's current projects. "This is a company that's done the work to prove out technical innovations," said Calvert. "We focus on clean air, clean water, and a clean Earth, so we're an environmental engineering group, and we have incredible innovations that are finding their way to market," he continued. "We're really a sustainable solutions provider." 

"Please give my listeners an update on your PFAS solution. Does it really work, how big is it, and what is the opportunity going forward?", asked Jolly. "The Biden Administration has really made this a priority," explained Calvert, adding that PFAS can be found in our water, bodies, and products. "It has been linked to adverse health effects." 

"We started on PFAS about a year and a half to two years ago, and we are now building our first commercial units. We have four commercial trials, two are confirmed and two are in the works," shared Calvert. "This is big business." 

Jolly then asked about the company's balance sheet improvements over the past two to three quarters, specifically related to the reduction of debt obligations. "We have this depth of talent that would rival the largest companies in the world," said Calvert. "We took some risks, we brought in a lot of money, we had some debt, it was expensive," he continued. "Now that's coming to an end," said Calvert. "A very small number will come due in August, it's convertible," he explained. "All in, it was about $5 million, and we're down to about $400,000 [in corporate debt obligations]," Calvert added. "The future is so bright, the commercial opportunities are so expansive, and the innovations are the real deal." 

The conversation then turned to the Company's Garratt-Callahan partnership. "First of all, this is just a wonderful company. They're a hundred plus years old, they are a national player, and they have a huge sales force," said Calvert. Added Calvert, "Since the inception, we thought [the relationship] would expand beyond the initial focus and it has. We're already working on some projects with some of their clients, and that is the start of something that could be really great." 

"Why should investors take a look at BioLargo?", asked Jolly. Calvert responded, "The things we are doing are massive, and the technology is proven. Now we get to enjoy the adoption cycle.  This is a company that is highly committed to investing in the business, deferring [management] compensation, and making sure that this company has the right people and the tools to go out and do something extraordinarily special. Everything we are doing we believe is number one in its category." 

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7818110-biolargo-inc-discusses-commercial-pfas-treatment-trials-and-garratt-callahan-partnership-with-t

 Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act - Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media

(602) 821-1102

Thursday, 4 March 2021

Proactive Investors Interview: BioLargo retires $650,000 in debt, following its plan to focus more on equity-based transactions

Source: Proactive Investors

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive it has paid off $650,000 in debt, the bulk of which was scheduled to mature in August 2021. Calvert says aside from the debt carried by its partially owned subsidiary Clyra Medical, only SBA loans and fixed-price convertible debt remain on BioLargo's balance sheet, which falls in line with the company's goals to aggressively reduce or eliminate its convertible debt instruments in favor of equity-based transactions.

Wednesday, 3 March 2021

BioLargo Invited to Present at Isle Utilities Industrial Water Treatment Virtual Event

Westminster, CA – March 3, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced that it has been invited to present its AOS (Advanced Oxidation System) water treatment technology to decision-makers from diverse multinational companies at an Isle Utilities iTAG event.

At Isle Utilities’ iTAG (Industrial Technology Approval Group) events, which are held three times per year, water specialists, sustainability/innovation managers and other experts from global industries vote on promising water technologies they would like to learn about. Some iTAG member companies include Coca-Cola, Shell, and Proctor & Gamble.

In the March 2021 meeting, iTAG member companies voted to learn about BioLargo’s AOS technology. BioLargo Director of Strategic Marketing and Business Development Tonya Chandler will present the BioLargo AOS to iTAG member companies on March 4, 2021.

To learn more about the TAG program, watch Isle Utilities’ video:

BioLargo’s ground-breaking and patented Advanced Oxidation System (AOS) is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies. Distinct from other disinfection-focused treatment systems, the AOS can also remove certain pharmaceutical micropollutants from water to provide added value across diverse water treatment applications.

The timing of BioLargo’s invitation to present at iTAG is auspicious, as the company is beginning to roll out the AOS through commercial trials, beginning with its first farm-wide water treatment and reuse project at a poultry farm in Alberta, Canada.

To learn more about the BioLargo AOS, visit www.biolargowater.com.

 

About Isle Utilities and iTAG

Isle is a medium sized, worldwide operating consultancy that has bridged exactly that gap successfully over the past decade for more than 150 global utilities. With 40 highly educated water professionals located all over the globe, Isle scouts, assesses and selects new water related technologies for the municipal water and wastewater utilities. In 2016, Isle has started to offer this service to industries with water and sustainability challenges too.  Each industrial company has sustainability objectives but it is typical that not all companies have the time to visit all the global trade shows, read every journal on the subject and invite all salesmen to site with that unique innovative solution to save water, energy and chemicals. At the same time, business developers of new innovative technologies have a hard time to draw the attention of these always extremely occupied industries. It was a catch 22 situation, until Isle set up iTAG.

Three times a year at iTAG-meetings (industrial Technology Approval Group) water specialists, sustainability/innovation managers and other experts from global industries gather. Some weeks prior to this meeting the members receive a list of the newest technological water related solutions which have been thoroughly vetted and compactly described by Isle’s experts. The members are invited to vote on the most promising technologies, which will be presented on the iTAG meeting. Over the last 10 years Isle has evaluated over 100 new technologies each year, varying from well protection technologies, treatment technologies, innovative sensors to cooling water technologies, wastewater solutions and novel ways to recover nutrients, sludge and energy.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday, 2 March 2021

BioLargo Strengthens Balance Sheet by Eliminating Debt as its Commercial Activities Expand

Westminster, CA – March 2, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it had paid off $650,000 in debt, the bulk of which was scheduled to mature in August of 2021.  Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA loans and fixed-price convertible debt remain on BioLargo’s balance sheet. Of the SBA loans, management expects all but the $150,000 EIDL 30-year 3.75% APR loan to be forgiven. Of the fixed price convertible debt, $100,000 will convert to equity automatically at the April 20, 2021 maturity date, the $406,000 due in August 2021 may be converted by the investors at a fixed price of $0.14 at any time, and $50,000 is due in two years.

These actions are directly in line with the company’s goals to aggressively reduce or eliminate its convertible debt instruments in favor of equity-based transactions and eliminate costly interest expense. 

BioLargo President and CEO Dennis P. Calvert commented, “Our cash position is particularly strong, and we are confident in the progress of our business operations and expanding opportunities. Paying off this debt now helps reduce expense interest expense, as well as eliminate uncertainty of how the debt would be managed as it matures and comes due.”

Commercial milestones continue to grow at BioLargo with a few notable highlights:

·         An AOS water treatment unit was recently delivered to a municipal wastewater operation in Quebec Canada for pilot testing, and the company is on track for commencement of the AOS zero liquid discharge system project at poultry farm in Alberta, Canada, estimated to generate a half million dollars in revenue.

·         BioLargo’s engineering subsidiary continues to win major contracts with industrial clients, building a backlog of pending projects totaling more than $2 million over approximately the next 12 months. The group remains busy supporting BioLargo’s emerging commercial activities for the AEC and AOS water treatment systems.

·         BioLargo is exploring ways to expand its work with national water services company Garratt-Callahan beyond the development of a proprietary water treatment system.

·         Management is actively engaged with the EPA to expand its regulated claims for a series of products, including Clyraguard.

·         Expanded CupriDyne Clean misting system installations to municipal-owned solid-waste handling operations.

·         Readying for trials of the PFAS treatment solution (the BioLargo AEC) with multiple potential clients.

Dennis P. Calvert, BioLargo’s President & CEO commented, “We have solidified our reputation as a reliable innovator and solutions provider for sustainable high-value targets like clean water, clean air and a cleaner planet. We believe that our future revenue growth will accelerate dramatically through partnerships for large-scale manufacturing, distribution, and through marketing alliances. We have a strong foundation of technology, highly qualified team members and a driving purpose on which to build. As we have done for the last decade, innovations continue at BioLargo, and I’m personally very excited about some upcoming developments. We are proud of our record-breaking achievements but are certainly not satisfied as we believe we have only scratched the surface of our future revenue and profit potential.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Wednesday, 24 February 2021

BioLargo Answers Administration’s Urgent Call for Mitigation of PFAS Forever Chemicals

Highlights:

  • Federal enforcement of PFAS (per- and polyfluoroalkyl substances) in drinking water regulations is imminent
  • The water treatment sector is desperate for effective, economical solutions to remove PFAS from drinking water
  • BioLargo (OTCQB:BLGO) is rolling out its BioLargo AEC PFAS water treatment technology, which takes a novel and economical approach to removing these chemicals from water
  • The BioLargo solution produces far less PFAS-laden waste than traditional carbon-based technologies, leading to cost savings and a dramatically reduced carbon footprint
  • BioLargo’s PFAS solution will serve a multi-billion-dollar market while also aligning with the new administration’s focus on environmental issues such as water contamination

The Biden administration has wasted no time enacting new environmental policies since taking office last month. Our company, BioLargo (OTCQB:BLGO), is stepping up with exciting new technologies to take advantage of the opportunities created by President Biden’s far-reaching environmental agenda.

One of the new administration’s first moves was to announce final regulatory determinations on the safe levels of the widespread and toxic water contaminants called per- and polyfluoroalkyl substances (PFAS) in drinking water. This means the Federal Government has decided to create a national standard for what concentration of these chemicals will meet the threshold for regulatory action when found in drinking water supplies, and will now start the process of regulating the chemicals through the Safe Drinking Water Act.

The administration also gave advance notice that they may designate PFAS as federally regulated hazardous substances and/or regulated hazardous waste. These actions set off a long-anticipated race for municipalities around the country to identify and adopt water treatment systems that effectively and affordably remove the hard-to-treat chemicals from drinking water.

PFAS are a group of man-made chemicals found in countless household items like electronics, cleaning supplies, non-stick cookware and more. While many of these items are not known to be dangerous by virtue of containing PFAS, their ubiquitous manufacturing throughout the latter half of the 20th century led to widespread contamination of lakes, rivers, wells and groundwater throughout the U.S. In recent decades, there has been mounting evidence of the damage to human health caused by these chemicals, including cancer and hormone disorders.

Todd Haynes’s 2019 film Dark Waters told the story of how lawyer Robert Bilott (played by Mark Ruffalo) pursued DuPont in the late 1990s for contaminating Midwest communities with then-unregulated PFAS chemicals. While the issue of PFAS water contamination was well-documented by scientists at the time of the movie’s release, Dark Waters helped thrust the issue into the public eye.

In some areas such as Southern California, municipalities are already actively installing PFAS treatment systems, and as federal regulations go into effect, the adoption of PFAS treatment systems is expected to expand dramatically across the country. Drinking water utilities have struggled to find economical treatment technologies that can efficiently remove PFAS from water without stretching their budgets and generating mountains of toxic waste as a by-product of treatment. In Orange County, 11 water districts have launched a lawsuit against major PFAS polluters, including DuPont and 3M, to seek compensation for mandated well closures and water treatment system retrofitting needed to remove PFAS from their drinking water supplies.

At present, carbon filtration is the most common PFAS removal technology, but it comes with a serious downside – it generates huge volumes of PFAS-laden carbon waste that requires disposal. Usually, municipalities have to foot the bill for the costly transport and disposal of that PFAS-laden waste, which is normally done by incineration. Not only is PFAS carbon incineration costly, but a growing body of evidence suggests that it generates toxic volatile air contaminants (in addition to greenhouse gases) as a result of incomplete combustion of the PFAS chemicals. Disposal of PFAS-laden waste therefore remains a contentious issue (one that regulators are starting to look at) and municipalities would be wise to consider technologies that produce less PFAS-laden waste.  

Our company, BioLargo, an environmental technologies innovator (OTCQB:BLGO), has invented and is pilot-testing an innovative technology that removes PFAS chemicals from water faster and more cheaply than carbon filtration. Our technology, called the BioLargo AEC, uses electrolysis to extract PFAS molecules from water and deposit them onto proprietary membranes while using little electricity and no input chemistry. Proven to be more than 99.9% effective in removing PFAS from contaminated water, it produces only a fraction of the PFAS-laden waste that carbon filtration treatment creates, resulting in substantially lower waste disposal costs and better environmental outcomes.























How big is the market to solve this PFAS problem?

Experts have estimated that over the next decade, municipalities in the United States alone will spend billions of dollars a year on PFAS treatment systems. We at BioLargo aim to address this rapidly growing market by targeting municipalities interested in lower operating costs, decreased carbon footprints, increased constituent well-being and diminished regulatory risks associated with PFAS waste disposal. 

The BioLargo AEC is rolling out in pilots and commercial trials at municipalities in Southern California and the Midwest over the next year as more public officials and advocacy groups ratchet up the pressure to clean up the country’s PFAS contamination mess.

We at BioLargo are focused on creating a positive impact around the world with our innovative clean water, clean air and infection control solutions. Our company presents a scalable business model that targets high-impact CleanTech market opportunities like PFAS treatment while staying true to our mission statement to make life better.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.